"Desire to Eat" Is Born in the Brain, Not the Stomach? The Medicine of Desire Opened by GLP-1 Drugs

Discussions around GLP-1 drugs have traditionally focused on frameworks such as "how much weight can be lost," "how effective are they in treating diabetes," and "to what extent can side effects be tolerated." Medications like Ozempic, Wegovy, Mounjaro, and Zepbound are bringing significant changes to blood sugar and weight management, reshaping the conventional wisdom of obesity treatment.

However, recently, researchers' interests have begun to shift in a different direction. Are GLP-1 drugs merely suppressing "appetite," or are they affecting the very mechanism by which humans feel "desire" for something?

At the heart of the study covered by Ground News is precisely this question. Supported by the National Institutes of Health and published in Nature, the research suggests that next-generation oral small molecule GLP-1 receptor agonists may act on the reward circuits deep in the brain, potentially suppressing eating behaviors aimed at pleasure. What is important here is the behavior of eating not because "I'm hungry," but because "it looks delicious," "it makes me feel good," or "I just want to put something in my mouth."

In English-speaking regions, this is called "hedonic feeding." In Japanese, it can be translated as "pleasure-driven eating" or "reward-motivated eating behavior." Opening a bag of potato chips at midnight even when not hungry, seeking sweets due to work stress, or suddenly wanting dessert after seeing a picture of it even after a meal—such impulses are not merely issues of the stomach but are deeply connected to the brain's reward system.

The reason this study is attracting attention is that it has depicted the possibility that GLP-1 drugs reach even those reward systems as quite specific neural circuits.

GLP-1 Drugs Were Not Just "Fullness-Inducing Drugs"

GLP-1 is originally a type of hormone secreted in the body. It is secreted from the intestines when eating, helps insulin secretion, suppresses the rise in blood sugar levels, and slows the movement of stomach contents to the intestines. Through these actions, GLP-1-related drugs have been developed as diabetes treatments.

Eventually, it became clear that patients using GLP-1 drugs experienced weight loss, and their use as obesity treatments rapidly expanded. With the use of these drugs, it becomes easier to be satisfied with small meals, reducing overeating. Up to this point, the story is relatively straightforward.

However, listening to the voices of actual users, the changes cannot be explained by "getting full easily" alone. On social media and in patient communities, posts such as "I stopped thinking about food all day," "I open the refrigerator less often," and "I don't react to sweets as much as before" have been appearing one after another.

This phenomenon is often described as "food noise disappearing." Food noise is a colloquial term referring to a state where thoughts about food are constantly ringing in one's head. What to eat, when to eat, whether one can resist, and what to do if one eats—experiencing these thoughts becoming quiet is talked about as a more impressive change than weight loss for many GLP-1 drug users.

This study may provide a neuroscientific explanation for that sensation of "food noise quieting down."

The Central Amygdala as a "Relay Point of Desire"

The research team examined oral small molecule GLP-1 receptor agonists such as orforglipron and danuglipron. Many conventional GLP-1 drugs are injectable, using relatively large molecules called peptides. In contrast, small molecule drugs are expected to be easier to administer orally and easier to mass-produce.

However, there was a research difficulty with small molecule GLP-1 drugs. Many of them act on human GLP-1 receptors but do not act sufficiently on the receptors of normal mice, making it difficult to investigate mechanisms through animal experiments. Therefore, the research team used a model in which the GLP-1 receptor of mice was made closer to the human type to investigate which areas of the brain the drugs activate.

What emerged was the central amygdala.

The amygdala is known as a brain region involved in fear, anxiety, emotions, and desires. The central amygdala, in particular, is an important area involved in the regulation of emotions, desires, and behaviors. Until now, the appetite-suppressing effects of GLP-1 drugs have often been explained by areas such as the hypothalamus and brainstem, which manage energy homeostasis. In other words, circuits that determine whether the body needs energy, what signals are coming from the gastrointestinal tract, and whether one is full or hungry.

However, in this study, it was shown that oral small molecule GLP-1 drugs activate neurons with GLP-1 receptors in the central amygdala, suppressing dopamine release to the nucleus accumbens, the core of the reward system. Dopamine is often simplified as a "pleasure substance," but more accurately, it is an important neurotransmitter involved in reward prediction, desire, motivation, and learning.

In other words, this drug may work not only in the direction of "not eating because I'm full" but also in the direction of "weakening the reward signal that makes me want to eat it."

A Drug That Changes "Desire" Rather Than "Hunger"

What makes this discovery interesting is that it further challenges the view of treating obesity as merely a matter of willpower.

Many people think of overeating as a lack of self-control or inability to manage oneself. However, when the brain's reward circuit reacts strongly to certain foods, especially those high in sugar and fat, it is not easy to continue suppressing that desire with one's willpower alone. The impulse to eat is not merely a thought but a motivation supported by neural circuits.

What this study suggests is the possibility that GLP-1 drugs are directly involved in that motivation. If it were only about suppressing hunger, it would be a matter of the gastrointestinal tract or hypothalamus. However, if the pleasurable desire to eat weakens, it becomes a matter of the reward system. This significantly broadens the meaning of obesity treatment.

The fact that many users on social media describe their appetite as "quiet as if it were someone else's" aligns with this point. Of course, experiences shared on social media are not scientific evidence in themselves. Experiences can vary greatly depending on the type of drug, dosage, lifestyle, psychological state, and medical history. Nonetheless, the fact that more voices express "not being controlled by food" rather than "eating less" provides researchers with an undeniable hint.

Reactions on Social Media: A Mix of Agreement, Expectations, and Concerns

Topics related to this study are spreading on platforms like X, Reddit, and LinkedIn. Reactions are largely divided into three categories.

First, there are voices that welcome the explanation for why "food noise disappears." In GLP-1 drug user communities, the experience of weakened obsession with food has been repeatedly shared. In a Reddit thread, users reacted to the study that GLP-1 drugs change the brain's response to food cues by saying it matches their own experiences. In another post, there were comments expressing the feeling that "the brain capacity used for food seems to have been freed up."

Second, there is the expectation that it might affect desires beyond food. Behaviors involving the reward system are not limited to eating, such as alcohol, nicotine, shopping, gambling, and the obsession with sweet scents. There are personal posts about how the desire to drink alcohol weakened or impulsive buying decreased after starting GLP-1 drugs, or conversely, becoming fixated on another target. While these stories are still anecdotal, the commonality of acting on the reward circuit is why researchers are considering applications for substance use disorders and binge eating.

Third, there are voices of anxiety and caution. The fact that it acts on the brain's reward circuit means it could affect not only appetite but also joy, motivation, and emotional balance. On social media, while some people positively receive the idea of a "desire-calming drug," others express concerns like "will it dull enjoyment?" or "will it change my personality?" In fact, some people report changes in mood, motivation, and pleasure, in addition to nausea and gastrointestinal symptoms with GLP-1 drugs, and it is necessary to carefully determine how generalizable these effects are scientifically.

What is important here is not to overestimate the voices on social media. People with strong experiences are more likely to post on social media, and it is difficult to separate the effects of the drug from changes in living environment. However, the words of patients themselves can reveal changes that are not easily visible through clinical trial numbers alone. By illuminating each other, research and personal experiences gradually reveal the true nature of GLP-1 drugs.

Is There a Potential for Application in Addiction Treatment?

The research team and NIH are particularly focused on the possibility that GLP-1 drugs may affect reward behaviors beyond food. If dopamine release is regulated through the circuit from the central amygdala to the reward system, it may also relate to cravings for alcohol and drugs.

Preclinical and observational studies on the relationship between GLP-1 drugs and addiction are already underway. There are studies investigating their effects on alcohol consumption, nicotine, and cocaine-seeking behavior. If GLP-1 drugs can alleviate excessive reactions of the reward system, they could emerge as potential adjuncts in addiction treatment.

However, there is a major caveat here. The current Nature study was conducted using mice and does not directly demonstrate that "human addiction can be cured." Moreover, it is not a simple matter of just weakening the reward system. The reward system is essential for human-like behaviors such as eating, learning, interacting with others, striving, and gaining a sense of achievement. The boundary between suppressing excessive desires and diminishing life's pleasures and motivation must be carefully considered.

In that sense, research on GLP-1 drugs is beginning to expand from "weight loss drugs" to the deeper medical theme of "how to regulate desire."

Do Not Confuse "Ozempic's Brain Effects" with This Study

In the media, this topic is sometimes described with headlines like "Ozempic Changes the Brain." While this is an understandable expression to attract readers' interest, scientific caution is needed.

The current Nature study mainly dealt with oral small molecule GLP-1 receptor agonists like orforglipron and danuglipron. Meanwhile, Ozempic is an injectable GLP-1 drug with semaglutide as its ingredient, differing in structure and administration route. While they fall under the same large category of GLP-1 drugs, the way they reach the brain, their action on receptors, duration, and side effects differ for each drug.

Of course, existing GLP-1 drugs like semaglutide are also thought to have effects on the brain. Their involvement with the hypothalamus, brainstem, and reward system is also being researched. However, the "circuit shown in this mouse study of small molecule drugs" does not apply to all GLP-1 drugs and all humans.

Misunderstanding this could lead to either elevating GLP-1 drugs as a panacea or excessively fearing them as "dangerous drugs that manipulate the brain." What can be said at this point is that the effects of GLP-1 drugs cannot be explained solely by the gastrointestinal tract or blood sugar, and the possibility of their involvement in brain reward, emotion, and motivation is increasingly strong.

Potential Impact on the Food Industry and Society

The spread of GLP-1 drugs is beginning to have effects beyond healthcare. If appetite and cravings for snacks weaken, it could affect purchasing behavior, dining out frequency, and the sales of snacks and sweet drinks. In fact, there is increasing reporting and market research analyzing changes in shopping and dining out behaviors among GLP-1 drug users.

If "pleasure-driven eating" behavior changes on a large scale due to drugs, it would be a significant structural change for the food industry. Products that provide high-calorie satisfaction and are prone to impulse buying, such as snacks and fast food, have been sold by tapping into consumers' brain rewards. If GLP-1 drugs weaken that reward response, companies may need to shift their strategies to products that offer satisfaction with smaller quantities or emphasize nutritional value.

On the other hand, a society where appetite changes due to drugs also raises ethical issues. It is important that the drugs reach those who need them for obesity or diabetes treatment, but if social pressure on weight and appearance increases, there is a possibility that even those with low medical necessity may seek the drugs. Additionally, the issue of how to respect the enjoyment of eating and the diversity of body types cannot be avoided.

GLP-1 drugs are not only changing individual body weight but are also spreading ripples across food culture, beauty standards, consumer behavior, and healthcare economics.

Research Limitations and Points to Watch Going Forward

While this study is very intriguing, conclusions should not be rushed.

First, the research was conducted on mice. Although mice with GLP-1 receptors closer to the human type were used, it does not perfectly replicate the complex eating behaviors and emotions of humans.

Second, the study mainly focused on oral small molecule GLP-1 drugs, and the same mechanism may not apply to all existing injectable GLP-1 drugs.

Third, it is still unknown what long-term effects suppressing hedonic feeding may have. While there are benefits like weight loss and blood sugar improvement, it is necessary to track long-term changes in mood, motivation, dependency tendencies, and eating behaviors.

Fourth, the effects of the drug vary greatly among individuals. For some, it may be "freedom from being controlled by food," while for others, it may feel like "a sense of diminished enjoyment." Medicine must consider individual differences, not just averages.

Going forward, important areas will include brain imaging studies on humans, clinical trials for addiction and binge eating, and tracking long-term mental and cognitive effects. Since GLP-1 drugs are already used by many people, understanding their effects after the fact is too late. Careful verification is required at the same pace as their spread.

GLP-1 Drugs Reexamine "Will" and "Desire"

The biggest question that GLP-1 drug research poses to society may be "to what extent is desire truly one's own?"

We usually perceive the sensations of wanting to eat, drink, buy, smoke, or taste again as part of our will or personality. However, from a neuroscience perspective, these are born from a combination of brain circuits, hormones, neurotransmitters, past learning, and environmental stimuli.

GLP-1 drugs can pharmacologically alter part of that. Therefore, they hold the potential to be a salvation for those suffering from obesity, diabetes, or addiction. On the other hand, there is naturally discomfort and anxiety about adjusting desires with drugs.

At the very least, this study has further outdated the view of overeating and obesity as mere laziness. Appetite is not just a matter of the stomach. Desire is not just a matter of personality. The circuits deep in the brain quietly influence our daily choices.